Eli Lilly diabetes drug Mounjaro in short supply, FDA says

The U.S. Food and Drug Administration has declared a shortage of Eli Lilly’s Mounjaro, the latest diabetes drug to be in short supply.

Due to increased demand for the medication, pharmacies may experience delays in receiving full shipments of the 5-milligram dose through January, according to a posting this week on the regulator’s website.

The FDA site says other doses are still available at this time, but the University of Utah drug information service – which tracks shortages through reports from pharmacies and providers – says the 2.5- and 7.5-milligram doses are also on intermittent backorder.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In